Accurate diagnosis is the foundation of effective treatment — and in neuromyelitis optica spectrum disorder, diagnosis has been transformed by antibody testing. The discovery of aquaporin-4 antibodies revolutionised understanding of the disease, distinguishing it from multiple sclerosis and enabling targeted therapy. This diagnostic advance is a major factor expanding the NMOSD market, as more patients are correctly identified and treated.

Testing for aquaporin-4 antibodies (AQP4-IgG) is now standard in suspected NMOSD. A subset of patients test negative for AQP4 antibodies but may have antibodies against myelin oligodendrocyte glycoprotein (MOG), defining a related but distinct condition. According to neuromyelitis optica spectrum disorder market research, wider availability of antibody testing — including cell-based assays with high sensitivity and specificity — is improving diagnostic accuracy and reducing misdiagnosis. This is particularly important because treatments effective in MS may worsen NMOSD, making correct diagnosis critical.

Diagnostic advances are also enabling earlier intervention. Patients identified at first attack can begin preventive therapy sooner, reducing the risk of cumulative disability. Biomarkers for monitoring treatment response and predicting relapse are being investigated, which could further refine care.

Challenges include access to testing in resource-limited settings, variability in assay performance, and the need for clinical expertise to interpret results. Yet the trend is clear: better diagnostics are expanding the treatable population and supporting market growth. As testing becomes more widespread, the NMOSD market will benefit from earlier diagnosis, more appropriate treatment, and improved patient outcomes.

People Also Ask

Q: How is NMOSD diagnosed?
A: Diagnosis relies on clinical presentation, MRI findings, and antibody testing — particularly aquaporin-4 antibodies — to distinguish it from multiple sclerosis.

Q: Can NMOSD be misdiagnosed as multiple sclerosis?
A: Yes, it was historically confused with MS; antibody testing now helps differentiate the conditions, which is critical because treatments differ.

Tags: #NMOSDDiagnosis #AntibodyTesting #Aquaporin4 #Neuroimmunology #Diagnostics #MarketGrowth